Adrian Ibrahim

Adrian brings over 30 years of experience in the life sciences spanning academia and biotech with a proven track record as a company founder and executive leader. A strategic leader with deep expertise in company creation and technology commercialisation, Adrian was the founding CEO of Mosaic Therapeutics, securing a US$28m Series A investment from blue-chip investors and building the team that secured a clinical candidate within three years of first institutional investment. Prior to this, as Head of Technology Translation and Business Development at the Wellcome Sanger Institute for over a decade, he built the technology translation function, spun out multiple companies, and led the transaction that created the globally recognised Open Targets pharma consortium.